Global Markets Direct’s pharmaceuticals report, “Vaxin, Inc. - Product Pipeline Review - 2013” provides data on the Vaxin, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Vaxin, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Vaxin, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
- Vaxin, Inc. - Brief Vaxin, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Vaxin, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Vaxin, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Vaxin, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Vaxin, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Vaxin, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Vaxin, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Vaxin, Inc.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Vaxin, Inc. and identify potential opportunities in those areas.
Table Of Contents
Vaxin, Inc. - Product Pipeline Review - 2013 Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Vaxin, Inc. Snapshot 4 Vaxin, Inc. Overview 4 Key Information 4 Key Facts 4 Vaxin, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Vaxin, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Vaxin, Inc. - Pipeline Products Glance 9 Vaxin, Inc. Clinical Stage Pipeline Products 9 Phase I Products/Combination Treatment Modalities 9 Vaxin, Inc. - Early Stage Pipeline Products 10 Preclinical Products/Combination Treatment Modalities 10 Vaxin, Inc. - Drug Profiles 11 AdVAV Anthrax Vaccine 11 Product Description 11 Mechanism of Action 11 RandD Progress 11 Alzheimer's Vaccine 12 Product Description 12 Mechanism of Action 12 RandD Progress 12 Epicutaneous Anthrax Vaccines 13 Product Description 13 Mechanism of Action 13 RandD Progress 13 Influenza Vaccine 14 Product Description 14 Mechanism of Action 14 RandD Progress 14 Tetanus Vaccine 15 Product Description 15 Mechanism of Action 15 RandD Progress 15 Vaxin, Inc. - Pipeline Analysis 16 Vaxin, Inc. - Pipeline Products by Therapeutic Class 16 Vaxin, Inc. - Pipeline Products by Route of Administration 17 Vaxin, Inc. - Recent Pipeline Updates 18 Vaxin, Inc. - Locations And Subsidiaries 19 Head Office 19 Appendix 20 Methodology 20 Coverage 20 Secondary Research 20 Primary Research 20 Expert Panel Validation 20 Contact Us 21 Disclaimer 21
List of Tables
Vaxin, Inc., Key Information 4 Vaxin, Inc., Key Facts 4 Vaxin, Inc. - Pipeline by Indication, 2013 6 Vaxin, Inc. - Pipeline by Stage of Development, 2013 7 Vaxin, Inc. - Monotherapy Products in Pipeline, 2013 8 Vaxin, Inc. - Phase I, 2013 9 Vaxin, Inc. - Preclinical, 2013 10 Vaxin, Inc. - Pipeline By Therapeutic Class, 2013 16 Vaxin, Inc. - Pipeline By Route of Administration, 2013 17 Vaxin, Inc. - Recent Pipeline Updates, 2013 18
List of Figures
Vaxin, Inc. - Pipeline by Indication, 2013 6 Vaxin, Inc. - Pipeline by Stage of Development, 2013 7 Vaxin, Inc. - Monotherapy Products in Pipeline, 2013 8 Vaxin, Inc. - Pipeline By Therapeutic Class, 2013 16 Vaxin, Inc. - Pipeline By Route of Administration, 2013 17